Analyst Price Target is $19.33
▲ +157.78% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $19.33, with a high forecast of $30.00 and a low forecast of $14.00. The average price target represents a 157.78% upside from the last price of $7.50.
Current Consensus is
Moderate Buy
The current consensus among 7 investment analysts is to moderate buy stock in Voyager Therapeutics. This Moderate Buy consensus rating has held steady for over two years.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Read More
